Fibrobiologics, Common Stock Stock Buy Hold or Sell Recommendation
| FBLG Stock | 1.17 0.06 4.88% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding FibroBiologics, Common Stock is 'Strong Sell'. Macroaxis provides FibroBiologics, Common buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding FBLG positions.
Check out FibroBiologics, Common Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as FibroBiologics, and provide practical buy, sell, or hold advice based on investors' constraints. FibroBiologics, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
FibroBiologics, |
Execute FibroBiologics, Common Buy or Sell Advice
The FibroBiologics, recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on FibroBiologics, Common Stock. Macroaxis does not own or have any residual interests in FibroBiologics, Common Stock or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute FibroBiologics, Common's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Abnormally volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
FibroBiologics, Common Trading Alerts and Improvement Suggestions
| FibroBiologics, Common generated a negative expected return over the last 90 days | |
| FibroBiologics, Common has high historical volatility and very poor performance | |
| FibroBiologics, Common may become a speculative penny stock | |
| Net Loss for the year was (16.48 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| FibroBiologics, Common generates negative cash flow from operations | |
| About 23.0% of the company shares are held by company insiders |
FibroBiologics, Common Returns Distribution Density
The distribution of FibroBiologics, Common's historical returns is an attempt to chart the uncertainty of FibroBiologics, Common's future price movements. The chart of the probability distribution of FibroBiologics, Common daily returns describes the distribution of returns around its average expected value. We use FibroBiologics, Common Stock price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of FibroBiologics, Common returns is essential to provide solid investment advice for FibroBiologics, Common.
| Mean Return | -1.03 | Value At Risk | -8.85 | Potential Upside | 8.57 | Standard Deviation | 6.60 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of FibroBiologics, Common historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
FibroBiologics, Common Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to FibroBiologics, Common or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that FibroBiologics, Common's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a FibroBiologics, stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -1.05 | |
β | Beta against Dow Jones | -0.1 | |
σ | Overall volatility | 6.65 | |
Ir | Information ratio | -0.14 |
FibroBiologics, Common Volatility Alert
FibroBiologics, Common Stock is displaying above-average volatility over the selected time horizon. FibroBiologics, Common Stock is a potential penny stock. Although FibroBiologics, Common may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in FibroBiologics, Common Stock. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on FibroBiologics, instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.FibroBiologics, Common Fundamentals Vs Peers
Comparing FibroBiologics, Common's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze FibroBiologics, Common's direct or indirect competition across all of the common fundamentals between FibroBiologics, Common and the related equities. This way, we can detect undervalued stocks with similar characteristics as FibroBiologics, Common or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of FibroBiologics, Common's fundamental indicators could also be used in its relative valuation, which is a method of valuing FibroBiologics, Common by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare FibroBiologics, Common to competition |
| Fundamentals | FibroBiologics, Common | Peer Average |
| Return On Equity | -2.68 | -0.31 |
| Return On Asset | -0.66 | -0.14 |
| Current Valuation | 36.33 M | 16.62 B |
| Shares Outstanding | 36.41 M | 571.82 M |
| Shares Owned By Insiders | 23.24 % | 10.09 % |
| Shares Owned By Institutions | 16.96 % | 39.21 % |
| Number Of Shares Shorted | 1.95 M | 4.71 M |
| Price To Book | 15.56 X | 9.51 X |
| EBITDA | (15.9 M) | 3.9 B |
| Net Income | (16.48 M) | 570.98 M |
| Total Debt | 1.75 M | 5.32 B |
| Book Value Per Share | 0.08 X | 1.93 K |
| Cash Flow From Operations | (6.4 M) | 971.22 M |
| Short Ratio | 4.06 X | 4.00 X |
| Earnings Per Share | (0.55) X | 3.12 X |
| Target Price | 12.75 | |
| Number Of Employees | 10 | 18.84 K |
| Market Capitalization | 42.6 M | 19.03 B |
| Total Asset | 11.82 M | 29.47 B |
| Retained Earnings | (24.36 M) | 9.33 B |
| Working Capital | 32 K | 1.48 B |
| Net Asset | 11.82 M |
Note: Acquisition by Ruben Garcia of 176200 shares of FibroBiologics, Common at 2.36 subject to Rule 16b-3 [view details]
FibroBiologics, Common Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as FibroBiologics, . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About FibroBiologics, Common Buy or Sell Advice
When is the right time to buy or sell FibroBiologics, Common Stock? Buying financial instruments such as FibroBiologics, Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having FibroBiologics, Common in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Furniture Thematic Idea Now
Furniture
Companies producing and selling home and office furniture. The Furniture theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Furniture Theme or any other thematic opportunities.
| View All Next | Launch |
Check out FibroBiologics, Common Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroBiologics, Common. If investors know FibroBiologics, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroBiologics, Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of FibroBiologics, Common is measured differently than its book value, which is the value of FibroBiologics, that is recorded on the company's balance sheet. Investors also form their own opinion of FibroBiologics, Common's value that differs from its market value or its book value, called intrinsic value, which is FibroBiologics, Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroBiologics, Common's market value can be influenced by many factors that don't directly affect FibroBiologics, Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroBiologics, Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroBiologics, Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroBiologics, Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.